Fresenius Kabi has a strong track record of manufacturing reliability, award-winning supply, and support offerings

Healthcare Common Procedure Coding System (HCPCS) Code1*

HCPCS Q-Code assigned to STIMUFEND for Centers for Medicare & Medicaid Services (CMS) claims processing effective for dates of service
on and after April 1, 2023.

HCPCS Code Description Sites of Service
Q5127 Injection, pegfilgrastim-fpgk,
biosimilar, (STIMUFEND), 0.5 mg
  • Physician office
  • Hospital outpatient
Billable Units Description Details
12 Billable units for administration
of 1 syringe
If applicable, discarded product should be reported on a separate line with Q5127 and the JW modifier

Payment status indicator2

Identifies whether a service represented by a CPT or HCPCS code is payable under the Outpatient Prospective Payment System (OPPS)
Ambulatory Payment Classification (APC) or another payment system. Only 1 status indicator is assigned to each CPT or HCPCS code.

HCPCS Code Description Status Indicator
Q5127 Injection, pegfilgrastim-fpgk,
biosimilar, (STIMUFEND), 0.5 mg

Download Billing and Coding Information

*The content provided on this page is for informational purposes only and is not intended as legal advice or to replace a medical provider's professional judgment. It is the sole responsibility of the treating healthcare professional to confirm coverage, coding, and claim submission guidance with the patient's health insurance plan. Fresenius Kabi does not guarantee STIMUFEND coverage or reimbursement. The information is current as of March 2023.

We support the needs of all decision-makers

Fresenius Kabi provides collaborative support that streamlines delivery of pegfilgrastim to more patients.

We are committed to addressing the needs of the oncology community with3:

  • Over 25 years of experience supplying oncology medications in the United States
  • One of the largest injectable oncology portfolios in the industry, with 82% of products filled and finished in the United States
  • Over 30 products used in more than 460 different chemotherapy regimens
  • Over 220 chemotherapy regimens that can be supported entirely by Fresenius Kabi

Winner of the FDA Drug Shortage Assistance Award.


Fresenius Kabi strives to make STIMUFEND consistently available

With 90 centers of science, manufacturing, and research and development around the globe, Fresenius Kabi can leverage a first-class supply chain to increase access to essential medicines and medical devices for patients. We plan to invest almost 1 billion dollars over the next few years in new US plants, to double production capacity, and in supply chain expansion, to build in supply chain redundancies. Our advanced manufacturing processes allow us to scale production to meet market needs.

We also partner closely with the FDA and other stakeholders, including other government agencies, pharmaceutical wholesalers, professional associations, and group purchasing organizations.


Product replacement program

Fresenius Kabi may provide healthcare professionals with a replacement of STIMUFEND

Offer applies to product that has been rendered unusable through unintentional, unplanned circumstances, including:

  • Product was mishandled, dropped, broken, or used incorrectly
  • Product was stored incorrectly
  • There was an unforeseen event that caused damage to the product
  • There was an error in mixing or preparing the product

To request a product replacement:

Fresenius Kabi reserves the right to reject a request for a product replacement in accordance with its STIMUFEND product replacement policy. Product dispensed through a specialty pharmacy is not eligible for product replacement. Additional eligibility requirements and limitations apply. See product replacement form for more details.

Fresenius Kabi has dedicated more than 100 years to supporting patient care

  1. Centers for Medicare and Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) application summaries and coding recommendations. Updated October 1, 2022. Accessed March 16, 2023.
  2. April 2023 update of the hospital outpatient prospective payment system (OPPS). Updated March 10, 2023. Accessed March 31, 2023.
  3. Data on file. Fresenius Kabi USA, LLC.

FDA, US Food and Drug Administration; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.